BioSante Pharmaceuticals, Inc. (BPAX)

[nutsyprofessor]

Two more comments and I'm done for the day.

From BioSante's last 10Q, dated August 2011:

1) "LibiGel — once daily transdermal testosterone gel in Phase III clinical development under a Special Protocol Assessment (SPA) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD)."

2) "We expect our cash and cash equivalents as of June 30, 2011, together with the net proceeds from our August 2011 public offering, to meet our liquidity requirements through at least the next 18 months."


Now you all can take all of this information tonight, study it closely, sleep on it, and then let's see if your perspective about LibiGel changes.

GLTA